Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ICOS Corporation -- Ignore unavailable to you. Want to Upgrade?

To: Lel H who wrote (706)	5/25/1999 11:05:00 AM
From: Edscharp	Read Replies (1) \| Respond to of 1139

This is from the Medical Technology Stock Letter - May 20, 1999 - Published by Jim McCamant: "ICOS' stock price is charging hard and may be a little ahead of itself in here. The company announced the addition of a new, undisclosed target to its drug discovery and development relationship with CombiChem. CombiChem will use its computerized drug-discover "engine" to generate new lead candidates for ICOS, and will receive up-front, milestone and royalty payments from any resultant commercialized products. ICOS is a buy under $30."